Revitalising India's Pharma Sector: Moving from Generics to Innovation

Revitalising India's Pharma Sector: Moving from Generics to Innovation

#GS-2 #Governance & Social Justice #Health #Government Policies & Interventions #GS-3 #Economy #Industrial Growth #Biotechnology

Key takeaways

  • India ranks as the 3rd-largest pharmaceutical producer globally by volume and exported medicines worth ₹2.46 lakh crore in FY 2024-25.
  • Despite manufacturing 20% of global generic medicines, India imports nearly 70% of its Active Pharmaceutical Ingredients (APIs) from China.
  • The government introduced the PLI Scheme for Bulk Drugs and the PRIP Scheme to boost domestic production of 41 critical drug products and advance biopharmaceutical research.
  • Public healthcare programs have established over 20,000 Pradhan Mantri Bharatiya Janaushadhi Kendras to provide generic medicines at 50% to 80% lower costs.

Why in News

  • India needs to transition from low-cost generic manufacturing to biopharmaceutical research and development.
  • Building a competitive research ecosystem requires securing raw material supply chains, enforcing quality rules, and balancing patent rights with public healthcare needs.

Key Developments Shaping India's Pharma Sector

  • Large manufacturing plants, lower production costs, and skilled scientific workers have made India a principal global supplier of generic medicines and vaccines.
  • India is the 3rd-largest pharmaceutical producer globally by volume and 11th by value, supplying nearly 20% of global generic medicines.
  • Pharmaceutical exports reached approximately ₹2.46 lakh crore in FY 2024-25, while imports stood at nearly ₹63,573 crore.
  • Leading Indian firms including Sun Pharma, Dr. Reddy's Laboratories, Cipla, Lupin, and Aurobindo Pharma maintain distribution networks across global markets.
  • The PLI Scheme for Bulk Drugs encourages local production of 41 critical bulk-drug products to decrease reliance on foreign suppliers.
  • The government is establishing 3 Bulk Drug Parks in Gujarat, Himachal Pradesh, and Andhra Pradesh with shared testing and waste treatment facilities.
  • Domestic manufacturing of essential materials like penicillin-G, clavulanic acid, and rifampicin is being revived to strengthen health security.
  • The PRIP Scheme supports industry-led research to help the sector move beyond generic drugs toward novel chemical entities and advanced drug delivery systems.
  • Centres of Excellence at NIPERs focus on developing new medical devices, bulk drugs, flow chemistry, and antimicrobial discovery.
  • Specialty drug portfolios, such as Sun Pharma's dermatology treatments, illustrate the sector shift from high-volume generics to high-margin specialized products.
  • Expiring patents on biological medicines create massive opportunities for Indian companies in biosimilars and cell-based therapies.
  • Firms like Biocon Biologics produce global biosimilar portfolios covering insulin and monoclonal antibodies for cancer and diabetes.
  • Vaccine manufacturers like Serum Institute of India, Bharat Biotech, and Biological E supply affordable vaccines like Rotavac, Corbevax, and HPV vaccines.
  • The BioE3 Policy, 2024 promotes biomanufacturing, precision biotherapeutics, smart proteins, and gene therapies across the country.
  • Recent safety alerts have increased focus on Good Manufacturing Practices, data integrity, and post-market safety surveillance.
  • The revised Schedule M under the Drugs Rules, 1945 aligns domestic factory standards with international WHO-GMP standards.
  • The Pharmacovigilance Programme of India monitors adverse drug reactions to ensure long-term patient safety after product release.
  • Meeting compliance standards set by authorities like the USFDA and European Medicines Agency is now essential for global competitiveness.
  • Artificial intelligence platforms, genomic databases, and health analytics are accelerating drug discovery and clinical testing.
  • Indian companies and start-ups such as Innoplexus, Bugworks Research, and Qure.ai use artificial intelligence platforms for healthcare research.
  • The GenomeIndia Project completed whole-genome sequencing for 10,000 individuals across 83 population groups to support population-specific research.
  • Factories are implementing digital twins, continuous manufacturing, and real-time analytical tools to replace traditional batch testing.
  • The expansion of domestic healthcare programs requires balancing export growth with affordable medicine access at home.
  • More than 20,000 Pradhan Mantri Bharatiya Janaushadhi Kendras were active by June 2026, targeting 25,000 centers by March 2027.
  • These government centers sell quality generic medicines at prices 50% to 80% lower than branded equivalents.
  • Expanding public health coverage through Ayushman Bharat-PM-JAY creates steady institutional demand for affordable government-procured drugs.
  • India is growing from a generic exporter into a hub for Contract Research, Development and Manufacturing Services (CRDMO).
  • Firms like Syngene International, Piramal Pharma Solutions, and Divi's Laboratories lead high-value contract research and custom synthesis.
  • Exporters are expanding into Europe, Latin America, Africa, and Asia to reduce financial risks tied to the United States market.
  • Domestic research initiatives are shifting the industry from volume-driven production toward intellectual-property-intensive novel discovery.
  • Supported by BIRAC, Nafithromycin (Miqnaf) by Wockhardt is India's first indigenously developed macrolide antibiotic for resistant infections.
  • The drug Zaynich represents another indigenous milestone against multidrug-resistant Gram-negative bacterial infections.
  • The Biopharma SHAKTI Mission aims to establish 3 new NIPERs, create 1,000 accredited clinical-trial sites, and expand CDSCO capacity.

Challenges

  • India imports nearly 70% of its Active Pharmaceutical Ingredients (APIs) and key starting materials directly from China.
  • Heavy import reliance for antibiotic raw materials like penicillin-G leaves the domestic medicine supply vulnerable to foreign supply shocks.
  • Foreign supply disruptions, geopolitical tensions, and trade restrictions create severe risks of drug shortages in local hospitals.
  • Incidents of contaminated or substandard medicines harm patient safety and damage India's reputation as the pharmacy of the world.
  • Contaminated cough syrups linked to child deaths in Gambia and Uzbekistan prompted WHO alerts regarding toxic chemical impurities.
  • Divided oversight between the CDSCO and State Drug Control Authorities creates inconsistent inspection standards across different states.
  • State agencies grant factory licenses while central bodies approve new drugs, leading to regulatory loopholes and fragmented oversight.
  • The absence of a centralized national drug recall mechanism delays the removal of harmful product batches from market shelves.
  • Most domestic companies focus on low-margin generic drugs rather than making long-term investments in original drug discovery.
  • Weak links between university research departments and commercial drug companies hinder the commercialization of new patents.
  • Relying on the United States for nearly one-third of pharmaceutical exports leaves Indian firms vulnerable to regulatory enforcement actions.
  • Warning letters and plant import alerts from the USFDA can shut down entire facilities and damage client trust.
  • Total exports reached USD 30.5 billion in FY 2024-25, but intense global generic competition continues to squeeze profit margins.
  • Widespread antibiotic misuse and over-the-counter purchases are accelerating dangerous Antimicrobial Resistance (AMR) across the country.
  • Reports from the ICMR Antimicrobial Resistance Surveillance Network highlight rising bacterial resistance against standard life-saving drugs.
  • Weak enforcement of prescription rules and limited antibiotic tracking in hospitals turn medicine access into a public safety concern.
  • Self-medication habits and incomplete treatment courses among patients further speed up the spread of drug-resistant pathogens.
  • Policymakers struggle to keep essential drugs affordable while providing adequate profit margins to fund novel biopharmaceutical research.
  • Out-of-pocket spending accounted for 39.4% of total health expenditure in 2021-22, making drug prices a major financial burden for families.
  • Price controls by the National Pharmaceutical Pricing Authority cover essential drugs, but advanced cancer therapies remain costly.
  • Aggressive price caps without supportive public procurement can discourage companies from developing complex generics and new treatments.

Way Forward

  • India should adopt a targeted security strategy for critical raw drug materials instead of relying only on broad production subsidies.
  • Public health systems can offer long-term purchasing guarantees to encourage local production of key raw materials like penicillin-G.
  • Developing shared industrial parks with common waste treatment facilities and power utilities will lower domestic API production costs.
  • Regulatory operations across state and central bodies should unite under a single transparent digital platform.
  • Assigning a Unique Pharmaceutical Identification Number to every product batch will enable complete tracking from factory to pharmacy.
  • A national e-inspection platform should assign auditors randomly and use past safety records to schedule targeted factory audits.
  • A dedicated government fund can share the financial risks of developing new biological drugs and original chemical entities.
  • Public research funding should release in stages as drug trials successfully clear clinical milestones and safety tests.
  • Introducing a patent-box tax regime can offer lower tax rates on income generated from drugs developed entirely within India.
  • Combining genetic and clinical data will help establish India as a global hub for diverse and ethical clinical research.
  • Clinical trials must include proper representation of women, elderly patients, and tribal groups to test drug safety across populations.
  • A secure digital health platform can combine hospital records and research datasets while protecting patient privacy.
  • Creating shared laboratory facilities will allow smaller companies to develop complex biosimilars and mRNA vaccines.
  • Regional hubs should provide shared pilot production units, cold-chain validation, and specialized safety testing services.
  • Strengthening scientific trade negotiations can help negotiate mutual inspection agreements with the EU, UK, and Japan.
  • Special support cells inside Indian embassies should guide small businesses on foreign regulatory filings and patent laws.
  • An early-warning tracking tool can alert domestic firms about upcoming patent expirations, regulatory changes, and overseas medicine shortages.
  • Health technology assessments should evaluate the actual clinical benefits of new medicines before setting public reimbursement prices.
  • Outcome-based purchasing contracts for expensive cancer treatments ensure that manufacturers receive full payment only if patients recover.
  • Forcing suppliers to display factory prices alongside retail margins will prevent excessive markups on branded generic medicines.
  • Strict environmental limits on antibiotic waste discharges must be enforced to prevent pharmaceutical pollution near production plants.
  • A Green Pharmaceutical Rating system can evaluate factory water usage and emissions, giving procurement preference to eco-friendly plants.
  • Linking factory pollution monitoring with ICMR surveillance networks will highlight regions where waste runoff accelerates drug resistance.

Conclusion

  • India must shift from being a high-volume generic manufacturer to becoming a global hub for advanced biopharmaceuticals and precision medicine.
  • By using stable generic revenues to finance research and securing raw material independence, India can remain the pharmacy of the world while leading medical innovation.